{
  "report_rows": [
    {
      "kpi": "Total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.071B vs. cons $1.054B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.68 vs. cons $2.56",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Clear Aligner case shipments",
      "prediction": "BEAT",
      "answer": "pred ~704k cases vs. cons 695k cases",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 revenue growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~3.5% vs. cons 3.5% (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 non-GAAP operating margin",
      "prediction": "UNCHANGED",
      "answer": "guide ~23.7% vs. cons 23.7% (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Q3 total revenue",
      "prediction": "LOWER",
      "answer": "guide ~$1.005B vs. cons $1.025B (Q3'26)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.5,
  "day5_path": "FADE",
  "day5_rationale": "A ~$1.071B revenue result versus $1.054B consensus and ~$2.68 EPS versus $2.56 support an initial positive reaction, but reaffirming ~3.5% FY26 growth versus 3.5% consensus while guiding Q3 revenue near $1.005B versus $1.025B leaves weaker implied second-half revenue and margin absorption. That out-period reset should pull FY26/FY27 estimates lower after the headline beat.",
  "day5_confidence": "MEDIUM"
}